{"id":1039,"date":"2025-02-07T12:15:00","date_gmt":"2025-02-07T11:15:00","guid":{"rendered":"https:\/\/lensounds.com\/2025\/02\/07\/framatome-and-iba-to-partner-to-develop-an-astatine-211-cyclotron-network-in-europe-and-the-usa\/"},"modified":"2025-02-07T12:15:00","modified_gmt":"2025-02-07T11:15:00","slug":"framatome-and-iba-to-partner-to-develop-an-astatine-211-cyclotron-network-in-europe-and-the-usa","status":"publish","type":"post","link":"https:\/\/atonco-pharma.com\/en\/2025\/02\/07\/framatome-and-iba-to-partner-to-develop-an-astatine-211-cyclotron-network-in-europe-and-the-usa\/","title":{"rendered":"FRAMATOME AND IBA TO PARTNER TO DEVELOP AN ASTATINE-211 CYCLOTRON NETWORK IN EUROPE AND THE USA"},"content":{"rendered":"<p><strong>Framatome &#038; IBA<\/strong> \u2013 Press Release<br \/>Paris, France and Louvain-La-Neuve, Belgium \u2013 February 7, 2025<\/p>\n<p>Framatome, an international leader in nuclear energy committed to developing products and services for the healthcare industry, and IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the leading provider of radiopharmaceutical production solutions, today announced they have signed a Memorandum Of Understanding to start a strategic partnership aimed at advancing industrial-scale production of Astatine-211 (<sup>211<\/sup>At), an alpha-emitting radioisotope across Europe and the United States.<\/p>\n<p><sup>211<\/sup>At is a highly promising radioisotope currently being investigated for its potential in targeted alpha-therapies in oncology. The collaboration between Framatome and IBA aims to build a reliable and sustainable network of cutting-edge specialized alpha-emitting cyclotrons, ensuring the timely and consistent production of this alpha-emitting radioisotope, whilst further establishing radio-theranostics as a cornerstone of precision oncology.<\/p>\n<p>The first milestone in this collaboration will be the establishment of a dedicated production pilot facility, set to be installed by 2027-2028. Framatome will make a financial investment in the partnership, with IBA contributing equipment. The facility will be located in the <strong>Pays de la Loire region in France<\/strong>, leveraging the region&#8217;s strong nuclear medicine research ecosystem and industrial expertise.<\/p>\n<h3>Key Quotes<\/h3>\n<p><strong>Fran\u00e7ois Gauch\u00e9, Vice President of Framatome Healthcare:<\/strong> &#8220;This partnership with IBA is a significant step toward transforming cancer care through targeted alpha therapy. The secure, scalable, and timely supply of Astatine-211 is vital for addressing unmet medical needs, and we are committed to building a robust production network to serve the growing demand.&#8221;<\/p>\n<p><strong>Charles Kumps, President of IBA RadioPharma Solutions:<\/strong> &#8220;Today&#8217;s announcement is the start of what we believe will be a strong partnership with a shared goal: building a global, reliable industrial network for the timely production and commercialization of Astatine-211 compounds.&#8221;<\/p>\n<h3>R\u00e9f\u00e9rence<\/h3>\n<p><strong>Source :<\/strong> Framatome &#038; IBA Joint Press Release<\/p>\n<p><strong>Date :<\/strong> 7 f\u00e9vrier 2025<\/p>\n<p><strong>Lien vers l&#8217;article original :<\/strong> <a href=\"https:\/\/share.google\/uvsFhhyffeDCJ5fKU\" target=\"_blank\" rel=\"noopener\">T\u00e9l\u00e9charger le communiqu\u00e9 de presse (PDF)<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Framatome &#038; IBA \u2013 Press ReleaseParis, France and Louvain-La-Neuve, Belgium \u2013 February 7, 2025 Framatome, an international leader in nuclear energy committed to developing products and services for the healthcare industry, and IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the leading provider of radiopharmaceutical production solutions, today announced [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1009,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[47],"tags":[],"class_list":["post-1039","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-other-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Framatome &amp; IBA Partner to Develop Astatine-211 Cyclotron Network in Europe and USA<\/title>\n<meta name=\"description\" content=\"Framatome and IBA announce a strategic partnership to build an industrial-scale astatine-211 production network in Europe and the USA.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/atonco-pharma.com\/en\/2025\/02\/07\/framatome-and-iba-to-partner-to-develop-an-astatine-211-cyclotron-network-in-europe-and-the-usa\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Framatome &amp; IBA Partner to Develop Astatine-211 Cyclotron Network in Europe and USA\" \/>\n<meta property=\"og:description\" content=\"Framatome and IBA announce a strategic partnership to build an industrial-scale astatine-211 production network in Europe and the USA.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/atonco-pharma.com\/en\/2025\/02\/07\/framatome-and-iba-to-partner-to-develop-an-astatine-211-cyclotron-network-in-europe-and-the-usa\/\" \/>\n<meta property=\"og:site_name\" content=\"Atonco\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-07T11:15:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/07\/Untitled-design-9.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"410\" \/>\n\t<meta property=\"og:image:height\" content=\"240\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin27\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin27\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2025\\\/02\\\/07\\\/framatome-and-iba-to-partner-to-develop-an-astatine-211-cyclotron-network-in-europe-and-the-usa\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2025\\\/02\\\/07\\\/framatome-and-iba-to-partner-to-develop-an-astatine-211-cyclotron-network-in-europe-and-the-usa\\\/\"},\"author\":{\"name\":\"admin27\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/#\\\/schema\\\/person\\\/0abcc6ce783094b44c1902ff2a9283b5\"},\"headline\":\"FRAMATOME AND IBA TO PARTNER TO DEVELOP AN ASTATINE-211 CYCLOTRON NETWORK IN EUROPE AND THE USA\",\"datePublished\":\"2025-02-07T11:15:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2025\\\/02\\\/07\\\/framatome-and-iba-to-partner-to-develop-an-astatine-211-cyclotron-network-in-europe-and-the-usa\\\/\"},\"wordCount\":335,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2025\\\/02\\\/07\\\/framatome-and-iba-to-partner-to-develop-an-astatine-211-cyclotron-network-in-europe-and-the-usa\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/atonco-pharma.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/Untitled-design-9.jpg\",\"articleSection\":[\"Other news\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2025\\\/02\\\/07\\\/framatome-and-iba-to-partner-to-develop-an-astatine-211-cyclotron-network-in-europe-and-the-usa\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2025\\\/02\\\/07\\\/framatome-and-iba-to-partner-to-develop-an-astatine-211-cyclotron-network-in-europe-and-the-usa\\\/\",\"url\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2025\\\/02\\\/07\\\/framatome-and-iba-to-partner-to-develop-an-astatine-211-cyclotron-network-in-europe-and-the-usa\\\/\",\"name\":\"Framatome & IBA Partner to Develop Astatine-211 Cyclotron Network in Europe and USA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2025\\\/02\\\/07\\\/framatome-and-iba-to-partner-to-develop-an-astatine-211-cyclotron-network-in-europe-and-the-usa\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2025\\\/02\\\/07\\\/framatome-and-iba-to-partner-to-develop-an-astatine-211-cyclotron-network-in-europe-and-the-usa\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/atonco-pharma.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/Untitled-design-9.jpg\",\"datePublished\":\"2025-02-07T11:15:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/#\\\/schema\\\/person\\\/0abcc6ce783094b44c1902ff2a9283b5\"},\"description\":\"Framatome and IBA announce a strategic partnership to build an industrial-scale astatine-211 production network in Europe and the USA.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2025\\\/02\\\/07\\\/framatome-and-iba-to-partner-to-develop-an-astatine-211-cyclotron-network-in-europe-and-the-usa\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2025\\\/02\\\/07\\\/framatome-and-iba-to-partner-to-develop-an-astatine-211-cyclotron-network-in-europe-and-the-usa\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2025\\\/02\\\/07\\\/framatome-and-iba-to-partner-to-develop-an-astatine-211-cyclotron-network-in-europe-and-the-usa\\\/#primaryimage\",\"url\":\"https:\\\/\\\/atonco-pharma.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/Untitled-design-9.jpg\",\"contentUrl\":\"https:\\\/\\\/atonco-pharma.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/Untitled-design-9.jpg\",\"width\":410,\"height\":240},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2025\\\/02\\\/07\\\/framatome-and-iba-to-partner-to-develop-an-astatine-211-cyclotron-network-in-europe-and-the-usa\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FRAMATOME AND IBA TO PARTNER TO DEVELOP AN ASTATINE-211 CYCLOTRON NETWORK IN EUROPE AND THE USA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/\",\"name\":\"Atonco\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/#\\\/schema\\\/person\\\/0abcc6ce783094b44c1902ff2a9283b5\",\"name\":\"admin27\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/94e7a71a0ec4632d35d5add64525ba0c3aee8df62644926cb9b386812d7ccdfb?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/94e7a71a0ec4632d35d5add64525ba0c3aee8df62644926cb9b386812d7ccdfb?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/94e7a71a0ec4632d35d5add64525ba0c3aee8df62644926cb9b386812d7ccdfb?s=96&d=mm&r=g\",\"caption\":\"admin27\"},\"sameAs\":[\"https:\\\/\\\/pulsheart-medical.com\"],\"url\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/author\\\/admin27\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Framatome & IBA Partner to Develop Astatine-211 Cyclotron Network in Europe and USA","description":"Framatome and IBA announce a strategic partnership to build an industrial-scale astatine-211 production network in Europe and the USA.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/atonco-pharma.com\/en\/2025\/02\/07\/framatome-and-iba-to-partner-to-develop-an-astatine-211-cyclotron-network-in-europe-and-the-usa\/","og_locale":"en_US","og_type":"article","og_title":"Framatome & IBA Partner to Develop Astatine-211 Cyclotron Network in Europe and USA","og_description":"Framatome and IBA announce a strategic partnership to build an industrial-scale astatine-211 production network in Europe and the USA.","og_url":"https:\/\/atonco-pharma.com\/en\/2025\/02\/07\/framatome-and-iba-to-partner-to-develop-an-astatine-211-cyclotron-network-in-europe-and-the-usa\/","og_site_name":"Atonco","article_published_time":"2025-02-07T11:15:00+00:00","og_image":[{"width":410,"height":240,"url":"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/07\/Untitled-design-9.jpg","type":"image\/jpeg"}],"author":"admin27","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin27","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/atonco-pharma.com\/en\/2025\/02\/07\/framatome-and-iba-to-partner-to-develop-an-astatine-211-cyclotron-network-in-europe-and-the-usa\/#article","isPartOf":{"@id":"https:\/\/atonco-pharma.com\/en\/2025\/02\/07\/framatome-and-iba-to-partner-to-develop-an-astatine-211-cyclotron-network-in-europe-and-the-usa\/"},"author":{"name":"admin27","@id":"https:\/\/atonco-pharma.com\/en\/#\/schema\/person\/0abcc6ce783094b44c1902ff2a9283b5"},"headline":"FRAMATOME AND IBA TO PARTNER TO DEVELOP AN ASTATINE-211 CYCLOTRON NETWORK IN EUROPE AND THE USA","datePublished":"2025-02-07T11:15:00+00:00","mainEntityOfPage":{"@id":"https:\/\/atonco-pharma.com\/en\/2025\/02\/07\/framatome-and-iba-to-partner-to-develop-an-astatine-211-cyclotron-network-in-europe-and-the-usa\/"},"wordCount":335,"commentCount":0,"image":{"@id":"https:\/\/atonco-pharma.com\/en\/2025\/02\/07\/framatome-and-iba-to-partner-to-develop-an-astatine-211-cyclotron-network-in-europe-and-the-usa\/#primaryimage"},"thumbnailUrl":"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/07\/Untitled-design-9.jpg","articleSection":["Other news"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/atonco-pharma.com\/en\/2025\/02\/07\/framatome-and-iba-to-partner-to-develop-an-astatine-211-cyclotron-network-in-europe-and-the-usa\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/atonco-pharma.com\/en\/2025\/02\/07\/framatome-and-iba-to-partner-to-develop-an-astatine-211-cyclotron-network-in-europe-and-the-usa\/","url":"https:\/\/atonco-pharma.com\/en\/2025\/02\/07\/framatome-and-iba-to-partner-to-develop-an-astatine-211-cyclotron-network-in-europe-and-the-usa\/","name":"Framatome & IBA Partner to Develop Astatine-211 Cyclotron Network in Europe and USA","isPartOf":{"@id":"https:\/\/atonco-pharma.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/atonco-pharma.com\/en\/2025\/02\/07\/framatome-and-iba-to-partner-to-develop-an-astatine-211-cyclotron-network-in-europe-and-the-usa\/#primaryimage"},"image":{"@id":"https:\/\/atonco-pharma.com\/en\/2025\/02\/07\/framatome-and-iba-to-partner-to-develop-an-astatine-211-cyclotron-network-in-europe-and-the-usa\/#primaryimage"},"thumbnailUrl":"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/07\/Untitled-design-9.jpg","datePublished":"2025-02-07T11:15:00+00:00","author":{"@id":"https:\/\/atonco-pharma.com\/en\/#\/schema\/person\/0abcc6ce783094b44c1902ff2a9283b5"},"description":"Framatome and IBA announce a strategic partnership to build an industrial-scale astatine-211 production network in Europe and the USA.","breadcrumb":{"@id":"https:\/\/atonco-pharma.com\/en\/2025\/02\/07\/framatome-and-iba-to-partner-to-develop-an-astatine-211-cyclotron-network-in-europe-and-the-usa\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/atonco-pharma.com\/en\/2025\/02\/07\/framatome-and-iba-to-partner-to-develop-an-astatine-211-cyclotron-network-in-europe-and-the-usa\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/atonco-pharma.com\/en\/2025\/02\/07\/framatome-and-iba-to-partner-to-develop-an-astatine-211-cyclotron-network-in-europe-and-the-usa\/#primaryimage","url":"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/07\/Untitled-design-9.jpg","contentUrl":"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/07\/Untitled-design-9.jpg","width":410,"height":240},{"@type":"BreadcrumbList","@id":"https:\/\/atonco-pharma.com\/en\/2025\/02\/07\/framatome-and-iba-to-partner-to-develop-an-astatine-211-cyclotron-network-in-europe-and-the-usa\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/atonco-pharma.com\/en\/"},{"@type":"ListItem","position":2,"name":"FRAMATOME AND IBA TO PARTNER TO DEVELOP AN ASTATINE-211 CYCLOTRON NETWORK IN EUROPE AND THE USA"}]},{"@type":"WebSite","@id":"https:\/\/atonco-pharma.com\/en\/#website","url":"https:\/\/atonco-pharma.com\/en\/","name":"Atonco","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/atonco-pharma.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/atonco-pharma.com\/en\/#\/schema\/person\/0abcc6ce783094b44c1902ff2a9283b5","name":"admin27","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/94e7a71a0ec4632d35d5add64525ba0c3aee8df62644926cb9b386812d7ccdfb?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/94e7a71a0ec4632d35d5add64525ba0c3aee8df62644926cb9b386812d7ccdfb?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/94e7a71a0ec4632d35d5add64525ba0c3aee8df62644926cb9b386812d7ccdfb?s=96&d=mm&r=g","caption":"admin27"},"sameAs":["https:\/\/pulsheart-medical.com"],"url":"https:\/\/atonco-pharma.com\/en\/author\/admin27\/"}]}},"_links":{"self":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/posts\/1039","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/comments?post=1039"}],"version-history":[{"count":0,"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/posts\/1039\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/media\/1009"}],"wp:attachment":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/media?parent=1039"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/categories?post=1039"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/tags?post=1039"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}